THERMO FISHER SCIENTIFIC Reports 2.6% Decrease in Total Revenue for Quarter Ending June 30 2023
August 28, 2023
🌥️Earnings Overview
THERMO FISHER SCIENTIFIC ($NYSE:TMO)’s total revenue for the second quarter of the 2023 fiscal year was USD 10.7 billion, representing a decrease of 2.6% compared to Q2 of the previous fiscal year. Net income for this quarter also decreased by 18.1%, amounting to USD 1.4 billion. These figures were released in the company’s earnings report for FY2023 Q2 on July 26 2023.
Analysis
Analyzing THERMO FISHER SCIENTIFIC’s fundamentals with the help of GoodWhale, it is clear that this company has achieved moderate growth in revenue or earnings. According to Star Chart, THERMO FISHER SCIENTIFIC is classified as ‘rhino’, indicating that it is a company which has achieved a certain level of stability and growth. This makes THERMO FISHER SCIENTIFIC an attractive investment for investors looking for stable growth and a reasonable return on investment. THERMO FISHER SCIENTIFIC is also strong in asset, dividend, growth, and profitability. The company has been able to maintain a high health score of 9/10 considering its cashflows and debt, making it capable to safely ride out any crisis without the risk of bankruptcy. This further adds to its attractiveness for investors who are looking for a long-term investment with a good chance of providing solid returns. Overall, THERMO FISHER SCIENTIFIC is an attractive option for growth seeking investors who want a well-rounded and stable investment opportunity with the potential for solid returns. The company’s ability to remain strong through difficult times indicates that it is a reliable and safe option for investors. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for TMO. More…
| Total Revenues | Net Income | Net Margin |
| 43.52k | 5.72k | 14.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for TMO. More…
| Operations | Investing | Financing |
| 7.69k | -4.66k | -1.81k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for TMO. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 94.11k | 50.19k | 113.36 |
Key Ratios Snapshot
Some of the financial key ratios for TMO are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 18.4% | 15.7% | 16.6% |
| FCF Margin | ROE | ROA |
| 13.5% | 10.5% | 4.8% |
Peers
In the world of scientific research, Thermo Fisher Scientific Inc is a giant. They are a leading provider of laboratory equipment and services, and their products are used in a wide range of industries. They have a strong presence in the United States, Europe, and Asia, and their competitors are Yourgene Health PLC, Thyrocare Technologies Ltd, Agilent Technologies Inc. All three companies are similar in that they provide scientific research products and services, but each has its own strengths and weaknesses.
– Yourgene Health PLC ($LSE:YGEN)
Yourgene Health PLC is a molecular diagnostics company. The company offers genetic testing services for a range of conditions, including cancer, cardiovascular disease, and inherited disorders. Yourgene Health PLC has a market cap of 29.99M as of 2022 and a Return on Equity of -5.02%. The company’s products and services are used by healthcare professionals, patients, and research institutions worldwide.
– Thyrocare Technologies Ltd ($BSE:539871)
Thyrocare Technologies Ltd. is an Indian in-vitro diagnostics company that offers services in more than 1,200 towns and cities across India. It has a network of over 2,000 collection centres and over 5,000 authorised diagnostic centres. The company was founded in 1996 and has its headquarters in Mumbai, India.
Thyrocare Technologies Ltd. has a market cap of 34.57B as of 2022. The company’s Return on Equity is 21.9%.
Thyrocare Technologies Ltd. is an Indian in-vitro diagnostics company that offers services in more than 1,200 towns and cities across India. It has a network of over 2,000 collection centres and over 5,000 authorised diagnostic centres. The company was founded in 1996 and has its headquarters in Mumbai, India.
– Agilent Technologies Inc ($NYSE:A)
Agilent Technologies is a publicly traded company with a market capitalization of $38.18 billion as of 2022. The company’s return on equity for the same year was 19.27%. Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides products and services that enable customers to make discoveries and accelerate the pace of innovation in their laboratories and businesses. Agilent’s products and services are used in a wide range of applications, including genomics, proteomics, drug discovery, forensics, food safety, and environmental monitoring.
Summary
Thermo Fisher Scientific’s second quarter financial results for FY2023 revealed a 2.6% decrease in total revenue compared to the same period last year, amounting to USD 10.7 billion. Net income also decreased by 18.1%, amounting to USD 1.4 billion. From an investment perspective, this could be interpreted as a potential opportunity for investors as the stock may potentially become undervalued due to the company’s performance over this quarter. Furthermore, it could be argued that due to the decrease in revenues and net income, the company may be looking to take advantage of cost-saving measures to improve its overall profitability in the future.
Related Posts
Recent Posts
